RLYB Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -4452.36% compared to Rallybio's net margin of 21.63%. Rallybio's return on equity of -67.73% beat Pfizer's return on equity of 8.72%.

Rallybio has a consensus price target of $1.00, signalling upside risk potential of 119.93%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.92%. Given that Rallybio has higher upside potential than Pfizer, analysts believe Rallybio is more attractive than Pfizer.

Rallybio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Rallybio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.92% to investors and pays a quarterly dividend of $0.43 per share. Rallybio pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Rallybio quarterly revenues are $212K, which are smaller than Pfizer quarterly revenues of $13.7B. Rallybio's net income of -$9.4M is lower than Pfizer's net income of $3B. Notably, Rallybio's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio is 23.88x versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -4452.36% compared to Rallybio's net margin of 4.65%. Rallybio's return on equity of -67.73% beat Progyny's return on equity of 11.16%.

Rallybio has a consensus price target of $1.00, signalling upside risk potential of 119.93%. On the other hand Progyny has an analysts' consensus of $26.63 which suggests that it could grow by 15.71%. Given that Rallybio has higher upside potential than Progyny, analysts believe Rallybio is more attractive than Progyny.

Rallybio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.703%.

Rallybio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Rallybio quarterly revenues are $212K, which are smaller than Progyny quarterly revenues of $324M. Rallybio's net income of -$9.4M is lower than Progyny's net income of $15.1M. Notably, Rallybio's price-to-earnings ratio is -- while Progyny's PE ratio is 40.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio is 23.88x versus 1.78x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

ProKidney has a net margin of -4452.36% compared to Rallybio's net margin of -7275.65%. Rallybio's return on equity of -67.73% beat ProKidney's return on equity of --.

Rallybio has a consensus price target of $1.00, signalling upside risk potential of 119.93%. On the other hand ProKidney has an analysts' consensus of $5.60 which suggests that it could grow by 59.09%. Given that Rallybio has higher upside potential than ProKidney, analysts believe Rallybio is more attractive than ProKidney.

Rallybio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProKidney has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rallybio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio pays -- of its earnings as a dividend. ProKidney pays out -- of its earnings as a dividend.

Rallybio quarterly revenues are $212K, which are smaller than ProKidney quarterly revenues of $230K. Rallybio's net income of -$9.4M is higher than ProKidney's net income of -$16.7M. Notably, Rallybio's price-to-earnings ratio is -- while ProKidney's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio is 23.88x versus -- for ProKidney. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -4452.36% compared to Rallybio's net margin of -1366.49%. Rallybio's return on equity of -67.73% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Rallybio has a consensus price target of $1.00, signalling upside risk potential of 119.93%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.14 which suggests that it could grow by 29.4%. Given that Rallybio has higher upside potential than Recursion Pharmaceuticals, analysts believe Rallybio is more attractive than Recursion Pharmaceuticals.

Rallybio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rallybio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Rallybio quarterly revenues are $212K, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Rallybio's net income of -$9.4M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Rallybio's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio is 23.88x versus 29.16x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.